Alnylam and Isis partner to develop single-stranded RNAi technology
As part of the collaboration, Isis has co-exclusively licensed its single-stranded RNAi (ssRNAi) technology to Alnylam in exchange for upfront payments, R&D milestone payments, and royalties. The alliance
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.